Bundled Treatment Program Provides New Opportunities For Treating Physicians and Patients Facing Limited Options RICHLAND, WASHINGTON – February 5, 2020 – Isoray, Inc. (NYSE American: ISR) today announced an executed agreement with MIM Software to deliver a novel...
While brachytherapy continues to demonstrate positive outcomes with swift side effect resolution for prostate cancer treatment, the modality remains underutilized. In this episode, Dr. John Sylvester is joined by radiation oncologist Dr. Alex Hsi to discuss why the...
Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 31, 2020– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Patients with Newly Diagnosed Malignant Brain Tumors Now Eligible for Surgically Targeted Radiation Therapy TEMPE, Ariz. -- GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that the U.S. Food and...
Welcome to the Isoray Prostate Cancer Connect Podcast! In each episode of the new podcast series, Dr. John Sylvester and featured guests will talk in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. In this episode, Dr....
Welcome to the Isoray’s Prostate Cancer Connect Podcast! Each episode of the new podcast series, Dr. John Sylvester and featured guests will be talking in-depth about the current status and advancements in brachytherapy for prostate cancer treatment. Dr. John...
Record Revenue and Gross Profit Revenue Increased 48% Year-Over-Year RICHLAND, WASHINGTON – November 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
Conference Call is Tuesday, November 12, 2019 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – October 31, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WASHINGTON – October 29, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR) announced today that it will demonstrate its latest products at the American Brachytherapy Society’s (ABS) annual prostate brachytherapy workshop. The workshop is scheduled to take place...
Record Full Year Revenue Driven by 27% Growth in the Company’s Core Prostate Brachytherapy RICHLAND, WASHINGTON – September 24, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
Overall Ten-Year Biochemical Success Rate for Entire Group Was 96.2% Largest and Longest Followed Series of Cesium-131 Treated Patients Reported to Date RICHLAND, WASHINGTON – September 18, 2019 –A recent publication is drawing attention for its positive report on a...
Conference Call is Tuesday, September 24, 2019, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...